Market closed

Castle Biosciences/$CSTL

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Castle Biosciences

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Ticker

$CSTL

Sector

Health Care

Trading on

NASDAQ

Industry

Health Care Providers & Services

Headquarters

Friendswood, United States

Employees

710

Website

castlebiosciences.com

CSTL Metrics

BasicAdvanced

$732M

124.31 $0.21

0.98 -

Price and volume

Market cap

$732M

Beta

0.98

52-week high

$33.33

52-week low

$16.97

Average daily volume

353K

Financial strength

Current ratio

7.784

Quick ratio

7.451

Long term debt to equity

5.667

Total debt to equity

6.063

Interest coverage (TTM)

-2.13%

Management effectiveness

Return on assets (TTM)

-0.14%

Return on equity (TTM)

1.47%

Valuation

Price to earnings (TTM)

124.307

Price to revenue (TTM)

2.306

Price to book

1.66

Price to tangible book (TTM)

2.21

Price to free cash flow (TTM)

20.824

Growth

Revenue change (TTM)

62.43%

Earnings per share change (TTM)

-107.42%

3-year revenue growth (CAGR)

53.43%

3-year earnings per share growth (CAGR)

-44.64%

What the Analysts think about CSTL

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.

CSTL Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

CSTL Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

CSTL News

AllArticlesVideos

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

Business Wire·2 days ago

Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients

Business Wire·3 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CSTL

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Castle Biosciences stock?

Castle Biosciences (CSTL) has a market cap of $732M as of January 15, 2025.

What is the P/E ratio for Castle Biosciences stock?

The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 124.31 as of January 15, 2025.

Does Castle Biosciences stock pay dividends?

No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Castle Biosciences dividend payment date?

Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.

What is the beta indicator for Castle Biosciences?

Castle Biosciences (CSTL) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.